MA56019A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies - Google Patents

Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies

Info

Publication number
MA56019A
MA56019A MA056019A MA56019A MA56019A MA 56019 A MA56019 A MA 56019A MA 056019 A MA056019 A MA 056019A MA 56019 A MA56019 A MA 56019A MA 56019 A MA56019 A MA 56019A
Authority
MA
Morocco
Prior art keywords
diseases
treatment
pharmaceutical compositions
new compounds
related pharmaceutical
Prior art date
Application number
MA056019A
Other languages
English (en)
Inventor
Luke Jonathan Alvey
Florence Marie-Emilie Bonnaterre
Denis Bucher
Nicolas Desroy
Béranger Duthion
Hélène Marie Jary
Christophe Peixoto
Taoues Temal-Laïb
Amynata Tirera
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA56019A publication Critical patent/MA56019A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA056019A 2019-05-29 2020-05-25 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies MA56019A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1907616.5A GB201907616D0 (en) 2019-05-29 2019-05-29 Novel compounds and pharmaceutical compositons thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
MA56019A true MA56019A (fr) 2022-04-06

Family

ID=67385363

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056019A MA56019A (fr) 2019-05-29 2020-05-25 Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies

Country Status (22)

Country Link
US (1) US20220340548A1 (fr)
EP (1) EP3976189B1 (fr)
JP (1) JP7550174B2 (fr)
KR (1) KR20220015450A (fr)
CN (1) CN113924146A (fr)
AR (1) AR119028A1 (fr)
AU (1) AU2020281650A1 (fr)
BR (1) BR112021023900A2 (fr)
CA (1) CA3141683A1 (fr)
CL (1) CL2021003133A1 (fr)
CO (1) CO2021017656A2 (fr)
CR (1) CR20210586A (fr)
EA (1) EA202193281A1 (fr)
GB (1) GB201907616D0 (fr)
IL (1) IL288375A (fr)
MA (1) MA56019A (fr)
MX (1) MX2021013803A (fr)
PE (1) PE20220503A1 (fr)
PL (1) PL3976189T3 (fr)
SG (1) SG11202112652RA (fr)
TW (1) TW202110839A (fr)
WO (1) WO2020239658A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7360745B2 (ja) 2019-03-11 2023-10-13 インフラルクス ゲーエムベーハー Ｃ５ａ受容体の調節因子としての縮合ピペリジニル二環式化合物及び関連化合物
USD982434S1 (en) * 2021-08-31 2023-04-04 Level Up Dice LLC Dice storage container
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
CN115304605B (zh) * 2022-01-21 2023-10-03 陕西国际商贸学院 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
WO2024003209A1 (fr) * 2022-07-01 2024-01-04 F. Hoffmann-La Roche Ag Dérivés d'imidazo [4,5-c] pyridine en tant que modulateurs de sik pour le traitement de la polyarthrite rhumatoïde
WO2024104441A1 (fr) * 2022-11-17 2024-05-23 Insilico Medicine Ip Limited Inhibiteurs de kinases inductibles par sel (sik) et leurs procédés d'utilisation
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010534206A (ja) 2007-07-20 2010-11-04 メルク・シャープ・エンド・ドーム・コーポレイション ピラゾロ［１，５−ａ］ピリミジン誘導体
CN103282034A (zh) * 2010-11-18 2013-09-04 利亘制药公司 造血生长因子模拟物的用途
EP2646215A1 (fr) 2010-12-01 2013-10-09 Plasan Carbon Composites, Inc. Procédé et système permettant de former des articles composites
EP2825540B1 (fr) * 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Imidazolpyridazines substituées
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CN106496222A (zh) 2016-09-07 2017-03-15 华东师范大学 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用
CN111433200B (zh) 2017-12-02 2024-03-22 加拉帕戈斯股份有限公司 用于治疗疾病的化合物及其药物组合物
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用
US20220402911A1 (en) 2018-06-15 2022-12-22 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Also Published As

Publication number Publication date
CL2021003133A1 (es) 2022-07-22
PE20220503A1 (es) 2022-04-07
IL288375A (en) 2022-01-01
AU2020281650A1 (en) 2022-02-03
MX2021013803A (es) 2021-12-14
TW202110839A (zh) 2021-03-16
SG11202112652RA (en) 2021-12-30
CO2021017656A2 (es) 2022-01-17
US20220340548A1 (en) 2022-10-27
EP3976189B1 (fr) 2024-07-03
EP3976189A1 (fr) 2022-04-06
KR20220015450A (ko) 2022-02-08
PL3976189T3 (pl) 2024-09-09
EA202193281A1 (ru) 2022-03-01
WO2020239658A1 (fr) 2020-12-03
JP7550174B2 (ja) 2024-09-12
CN113924146A (zh) 2022-01-11
CR20210586A (es) 2022-01-24
EP3976189C0 (fr) 2024-07-03
CA3141683A1 (fr) 2020-12-03
BR112021023900A2 (pt) 2022-01-18
AR119028A1 (es) 2021-11-17
GB201907616D0 (en) 2019-07-10
JP2022534578A (ja) 2022-08-02

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51739A (fr) Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA52118A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA51524A (fr) Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA55497A (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
MA47503A (fr) Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
MA55604A (fr) Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
MA55218A (fr) Eskétamine pour le traitement de la dépression
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA50069A (fr) Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique
MA54873A (fr) Compositions et méthodes pour le traitement de troubles neurocognitifs
MA52960A (fr) Compositions et procédés pour la réduction ou le traitement de la fibrose